BBT

• UNSPSC Description:

  BBT is an enhancer of impaired glucose-stimulated insulin secretion (GSIS). BBT exhibits anti-hyperglycemia activity, and protects β-cells from cytokine- or streptozotocin (STZ (HY-13753))-induced cell death in type 2 diabetes models. BBT acts function via cAMP/PKA and long-lasting (L-type) voltage-dependent Ca2+ channel/CaMK2 pathway[1].

• Target Antigen:

  Calcium Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel;Neuronal Signaling

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/bbt.html

• Purity:

  99.71

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  C1(=CC=C(Br)S1)C(=O)NC1=CC=CC=C1C(C1C=CC=CC=1)=O

• Molecular Weight:

  386.27

• References & Citations:

  [1]Yao XG, et al. BBT improves glucose homeostasis by ameliorating 尾-cell dysfunction in type 2 diabetic mice. J Endocrinol. 2015 Mar;224(3):327-41.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  445000-45-3